Browse by author
Lookup NU author(s): Professor John IsaacsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020, Springer Nature Limited.Biologic agents have become a core component of therapeutic strategies for many inflammatory rheumatic diseases. However, perhaps reflecting the specificity and generally high affinity of biologic agents, these therapeutics have been used by rheumatologists with less consideration of their pharmacokinetics than that of conventional synthetic DMARDs. Immunogenicity was recognized as a potential limitation to the use of biologic agents at an early stage in their development, although regulatory guidance was relatively limited and assays to measure immunogenicity were less sophisticated than today. The advent of biosimilars has sparked a renewed interest in immunogenicity that has resulted in the development of increasingly sensitive assays, an enhanced appreciation of the pharmacokinetic consequences of immunogenicity and the development of comprehensive and specific guidance from regulatory authorities. As a result, rheumatologists have a greatly improved understanding of the field in general, including the factors responsible for immunogenicity, its potential clinical consequences and the implications for everyday treatment. In some specialties, immunogenicity testing is becoming a part of routine clinical management, but definitive evidence of its cost-effectiveness in rheumatology is awaited.
Author(s): Strand V, Goncalves J, Isaacs JD
Publication type: Review
Publication status: Published
Journal: Nature Reviews Rheumatology
Year: 2021
Volume: 17
Issue: 2
Pages: 81-97
Print publication date: 01/02/2021
Online publication date: 14/11/2020
Acceptance date: 03/11/2020
ISSN (print): 1759-4790
ISSN (electronic): 1759-4804
Publisher: Nature Research
URL: https://doi.org/10.1038/s41584-020-00540-8
DOI: 10.1038/s41584-020-00540-8
PubMed id: 33318665
